9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Enantioselective Box Behenken Optimized HPLC-DAD Method for the Simultaneous Estimation of Alogliptin Enantiomorphs in Pharmaceutical Formulations and their Pharmacokinetic Study in Rat Plasma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose: A stereoselective high performance liquid chromatographic analytical method with photodiode array detector was developed and validated as per the International Conference on Harmonization (ICH) guidelines for the determination of alogliptin (ALO) enantiomers in formulations and rat plasma.

          Methods: Enantiomeric separation was performed on a Phenomenex Lux Cellulose-2 chiral column. Box-Behnken design was used to identify the optimum conditions of the three independent variables for the desired output responses.

          Results: The HPLC peaks of ALO enantiomers and the internal standard pioglitazone were achieved before 8 min with a resolution of 0.77 min between R and S enantiomer and resolution of more than 2.0 between each enantiomer and pioglitazone (internal) with more than 95% recovery. The linearity range and the limit of quantification of both the enantiomers in rat plasma were 10-70 ng mL -1 and 1.2 ng mL -1 respectively.

          Conclusion: The developed method after validation was successfully applied for estimation of ALO enantiomers in formulations. Single oral dose of 25 mg of the ALO racemate tablets were administered to a group of 6 healthy rats for a comparative pharmacokinetic study of both the enantiomers.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.

          This study presents PKSolver, a freely available menu-driven add-in program for Microsoft Excel written in Visual Basic for Applications (VBA), for solving basic problems in pharmacokinetic (PK) and pharmacodynamic (PD) data analysis. The program provides a range of modules for PK and PD analysis including noncompartmental analysis (NCA), compartmental analysis (CA), and pharmacodynamic modeling. Two special built-in modules, multiple absorption sites (MAS) and enterohepatic circulation (EHC), were developed for fitting the double-peak concentration-time profile based on the classical one-compartment model. In addition, twenty frequently used pharmacokinetic functions were encoded as a macro and can be directly accessed in an Excel spreadsheet. To evaluate the program, a detailed comparison of modeling PK data using PKSolver and professional PK/PD software package WinNonlin and Scientist was performed. The results showed that the parameters estimated with PKSolver were satisfactory. In conclusion, the PKSolver simplified the PK and PD data analysis process and its output could be generated in Microsoft Word in the form of an integrated report. The program provides pharmacokinetic researchers with a fast and easy-to-use tool for routine and basic PK and PD data analysis with a more user-friendly interface. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Box-Behnken design: an alternative for the optimization of analytical methods.

            The present paper describes fundamentals, advantages and limitations of the Box-Behnken design (BBD) for the optimization of analytical methods. It establishes also a comparison between this design and composite central, three-level full factorial and Doehlert designs. A detailed study on factors and responses involved during the optimization of analytical systems is also presented. Functions developed for calculation of multiple responses are discussed, including the desirability function, which was proposed by Derringer and Suich in 1980. Concept and evaluation of robustness of analytical methods are also discussed. Finally, descriptions of applications of this technique for optimization of analytical methods are presented.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              FDA's policy statement for the development of new stereoisomeric drugs.

              (1991)
                Bookmark

                Author and article information

                Journal
                Adv Pharm Bull
                Adv Pharm Bull
                Adv Pharm Bull
                APB
                TBZMED
                Advanced Pharmaceutical Bulletin
                Tabriz University of Medical Sciences
                2228-5881
                2251-7308
                February 2019
                21 February 2019
                : 9
                : 1
                : 147-158
                Affiliations
                Pharmaceutical Chemistry Department, Delhi Institute of Pharmaceutical Sciences & Research, University of Delhi, Sector 3 Pushp Vihar, Mehrauli Badarpur Road, New Delhi -110017, India.
                Author notes
                [* ] Corresponding Author:Ravi Kant, Tel: +91-9910361406, Email: ravi.taurean@ 123456gmail.com
                Author information
                https://orcid.org/0000-0002-8850-8284
                https://orcid.org/0000-0002-1115-6436
                https://orcid.org/0000-0002-6872-414X
                Article
                10.15171/apb.2019.018
                6468233
                48d7160f-d593-4c6f-8a73-7204e886f942
                ©2019 The Authors.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

                History
                : 06 June 2018
                : 02 October 2018
                : 20 December 2018
                Page count
                Figures: 5, Tables: 8, References: 47, Pages: 12
                Categories
                Research Article

                alogliptin enantiomers,box–behnken design,pharmacokinetics,hplc-dad,spe

                Comments

                Comment on this article